Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EV-209: Enfortumab vedotin plus pembrolizumab for bladder preservation in muscle-invasive bladder cancer
2025-524488-18-00Phase 2Authorised
- Sponsor
- Astellas Pharma
- Start
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 2, open-label, single-arm trial of enfortumab vedotin and pembrolizumab in muscle-invasive bladder cancer (MIBC) and transitional cell carcinoma (TCC), sponsored by Astellas Pharma. Primary endpoints: Overall clinical complete response rate and 2-year bladder-intact event-free survival rate. Planned start Aug 2026; status: authorised.
02
Drugs
enfortumab vedotinpembrolizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2025-524488-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524488-18-00.